Savitr Capital

Immunis.AI operates a non-invasive liquid biopsy platform called Intelligentia, which focuses on providing diagnostic information to healthcare professionals for optimizing patient treatment. The platform utilizes advanced genomic analysis of blood samples to assess diseases, particularly in oncology, while also planning to expand its applications to metabolic, autoimmune, and neurodegenerative conditions. By employing machine learning, Intelligentia analyzes differential gene expression patterns to identify novel biomarkers and biological pathways associated with various diseases. This capability enhances the profiling of small tumors, supporting clinicians and pharmaceutical developers in areas such as screening, diagnosis, prognosis, and surveillance. Founded in 2012 and based in Royal Oak, Michigan, Immunis.AI was previously known as OncoCell MDx, Inc. before rebranding in January 2020.

Fidelis Pharmaceuticals offers exceptional expertise in the acquisition, development, and marketing of unique pharmaceutical formulations that meet specialized veterinary needs. Fidelis Pharmaceuticals is a privately held U.S.-based company serving the world from the Northeast pharmaceutical corridor. The company is headquartered in North Brunswick, New Jersey.

Glytec, LLC is a clinical information technology company that specializes in developing insulin management and glycemic control solutions for diabetes patients globally. Founded in 2006 and headquartered in Waltham, Massachusetts, with an additional office in Greenville, South Carolina, Glytec offers the eGlycemic Management System (eGMS), a cloud-based decision support system designed to enhance glycemic management. The eGMS features components such as SmartClick for direct access to patient applications, GlucoSurveillance for real-time insights into glycemic control, Glucommander for personalized insulin dosing recommendations, and GlucoMetrics for performance analytics. Additionally, Glytec provides Hospital-to-Home Discharge Recommendations to help patients transition back to home care effectively. By integrating evidence-based decision support with clinical services, Glytec aims to improve the safety and efficacy of insulin therapy, thereby reducing complications and hospital visits for diabetes patients.

Biora Therapeutics is a biotechnology company focused on developing innovative oral biotherapeutics that combine drug and device technologies. The company's primary aim is to enhance treatment approaches for patients by enabling targeted delivery of therapeutics directly to the gastrointestinal tract, particularly for conditions such as Inflammatory Bowel Disease (IBD). Additionally, Biora Therapeutics is working on systemic delivery methods that replace traditional injection techniques with needle-free, oral delivery systems. By advancing these biotherapeutic solutions, Biora Therapeutics seeks to improve patient outcomes and streamline the administration of medications, making treatments more accessible and effective.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

BioIQ also known as Jentryx is a health improvement technology company that has implemented the industry’s first integrated, customizable and measurable approach to optimizing investments in corporate health and wellness programs. The company’s unique health screening platform, ecosystem of health improvement tools, and proven methodology for obtaining quantifiable wellness insights are serving beneficiaries across the United States. BioIQ works with some of the largest employers and health companies in the nation and has launched over 3,000 successful health improvement programs since its inception in 2005.

OncoCellMDx is a privately held company dedicated to the development and commercialization of novel diagnostic tests utilizing proprietary technologies created at Harvard Medical School. In particular, They have developed a noninvasive blood-based immunogenomic assays that will aid the physician to better understand the underlying pathology. The first product is for assessing the severity of prostate cancer. Other oncology indications as well as non-oncology indications are part of their pipeline.

Ancora Heart is dedicated to helping people with heart failure feel better and live longer. Ancora Heart developed the AccuCinch System, an investigational therapy designed to repair the enlarged left ventricle targeting the underlying cause of heart failure. The AccuCinch heart failure treatment was created to benefit the millions of patients who otherwise have no minimally invasive option available to them.

Heron Therapeutics, Inc. is a biotechnology company based in San Diego, California, that focuses on developing innovative treatments to address unmet medical needs. The company utilizes its proprietary Biochronomer drug delivery technology, which enables sustained release of therapeutic agents over days to weeks with a single administration. Heron's product portfolio includes SUSTOL, an extended-release injection for preventing nausea and vomiting associated with chemotherapy, and CINVANTI, an intravenous formulation for similar indications. Additionally, the company is advancing HTX-011, a dual-acting combination of bupivacaine and meloxicam, currently in Phase III clinical trials for pain management, and HTX-034, aimed at postoperative pain relief. Founded in 1983, Heron Therapeutics was previously known as A.P. Pharma, Inc. before rebranding in 2014.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Naurex Inc. is a clinical-stage company based in Evanston, Illinois, focused on developing innovative therapies for depression and other central nervous system disorders. The company is pioneering a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a novel class of compounds known as glycine-site functional partial agonists (GFPAs). These compounds offer a different approach to receptor modulation compared to existing NMDAR agents. Naurex's drug development pipeline includes the first-generation molecule GLYX-13, as well as the second-generation NRX-1050 small molecule series and additional compounds derived from its platform of novel NMDAR modulators. The company's mission is to address unmet needs in psychiatry and neurology by providing safe and effective treatment options.

Svelte Medical Systems, Inc. specializes in the design, development, and commercialization of balloon-expandable stents aimed at patients undergoing percutaneous coronary intervention (PCI) for atherosclerosis treatment. The company offers the SLENDER Integrated Delivery System, a drug-eluting coronary stent-on-a-wire system that simplifies catheter use for transradial interventions, and the DIRECT Rapid Exchange System, which employs proprietary balloon designs to improve direct stenting and post-dilatation processes. Founded in 2007 by Robert, David, and Tim Fischell, Svelte is committed to addressing critical clinical challenges in the coronary stent market, focusing on enhancing stent deliverability, reducing costs, and improving device safety. The company has developed one of the lowest profile and most deliverable stents available, featuring advanced technology aimed at achieving better clinical outcomes for patients. Based in New Providence, New Jersey, Svelte operates within the $5 billion coronary stent market.

Vascular Therapies, Inc. is a biopharmaceutical company based in Cresskill, New Jersey, founded in 2001, that focuses on developing innovative treatments for patients requiring vascular access for hemodialysis. The company's primary product candidate, which includes sirolimus, has received orphan drug designations in both the United States and the European Union for its applications in dialysis vascular access. Vascular Therapies is dedicated to addressing significant unmet clinical needs, particularly concerning arteriovenous fistula creation, and offers biodegradable collagen implants aimed at reducing vascular anastomosis failure. Through its advancements, the company seeks to enhance clinical outcomes for patients undergoing dialysis and improve their quality of life.